More details to be added soon

Médecins Sans Frontières (MSF) brings medical humanitarian assistance to people affected by conflict, natural disasters, epidemics or exclusion from healthcare. Founded in 1971 in France, MSF is an international, independent medical humanitarian organisation running operational programs in 70 countries and employing over 60,000 people.

Our actions are guided by medical ethics and humanitarian principles. Our funds come from millions of private individual donors worldwide, allowing us to act fast to save lives. Emergency response has been at the core of our work, with activities ranging from vaccination, surgery, psychological care, paediatrics, nutrition and more. Over recent years, MSF has developed oncology activities focusing on women affected by breast and/or cervical cancer, in partnership with national health authorities in Mali and Malawi. Aimed at strengthening prevention, screening, diagnosis, treatment, palliative and support care, these activities are being expanded to more countries such as Papua New Guinea. 

We strive to bring down barriers that keep people from getting the treatment they need to stay alive and healthy. To do this, MSF Access advocates for the most effective medicines and health products to be available, affordable, and equitably accessible for the people we care for, and beyond.  

An affiliate organisation created in 1986, Epicentre conducts field epidemiology activities, research projects and training programs in support of MSF’s goals. Epicentre's strength lies in its ability to rapidly apply epidemiological methods in complex situations. Its expertise networks include research centres in Niger and Uganda. 

Officially launched in September 2017, HKSH Medical Group promotes public health and advanced medicine through a multi-faceted, coordinated approach across clinical services, medical education, scientific research and public health education. Members of the Group, including Hong Kong Sanatorium& Hospital, HKSH Healthcare, HKSH Eastern Medical Centre, HKSH Cancer Centre and HKSH Institute for Innovation & Professional Development, are dedicated to offering top-quality holistic care to patients.

Established in 1922, Hong Kong Sanatorium & Hospital is one of the key members of HKSH Medical Group and a leading private hospital in Hong Kong. Living up to its motto of ‘Quality in Service, Excellence in Care’, the Hospital is committed to serving the public as well as promoting medical education and research.

For more information about HKSH Medical Group, please visit http://www.hksh.com.

Omnihealth Practice operates as an integrated, multi-channel medical communications platform, connecting over 30,000 healthcare professionals across Asia with timely clinical updates and localized insights. Bridging global data with everyday local practice through our regular print publication and digital channels, we deliver practical clinical intelligence that empowers frontline clinicians to optimize patient care and drive the future of healthcare. 

Our platform strategically spans major high-impact specialties, including but not limited to oncology, hematology, cardiology, neurology, obstetrics and gynecology. By delivering structured updates, expert commentary, and critical developments—such as emerging clinical trial data, evolving safety profiles, and therapeutic guidelines—we ensure every practitioner remains at the forefront of modern medicine.

Beyond breaking news, the network supports lifelong professional development through Continuing Medical Education (CME) resources, including specialized case studies, webinar recordings, and expert interviews. Backed by our regional presence, Omnihealth Practice streamlines how vital information moves across healthcare workflows, helping providers seamlessly integrate modern clinical knowledge directly into daily patient care.

Mission Early is a new multi-stakeholder, global initiative bringing together like-minded individuals, organizations, companies, and existing initiatives who believe in the importance of delivering quality early cancer care, including early detection (screening, referral, and early diagnosis), and early treatment (timely treatment and early-stage treatment). 

Siemens Healthineers pioneers breakthroughs in healthcare. For everyone. Everywhere. Sustainably. The company is a global provider of healthcare equipment, solutions and services, with activities in more than 180 countries and direct representation in more than 70. The group comprises Siemens Healthineers AG, listed as SHL in Frankfurt, Germany, and its subsidiaries. As a leading medical technology company, Siemens Healthineers is committed to improving access to healthcare for underserved communities worldwide and is striving to overcome the most threatening diseases. The company is principally active in the areas of imaging, diagnostics, cancer care and minimally invasive therapies, augmented by digital technology and artificial intelligence. In fiscal 2025, which ended on September 30, 2025, Siemens Healthineers had approximately 74,000 employees worldwide and generated revenue of around €23.4 billion. Further information is available at siemens-healthineers.com. 

FUJIFILM is a global company operating across healthcare, imaging, electronics and business innovation. Guided by its purpose of enriching lives and contributing to society, FUJIFILM develops technologies that support disease prevention, diagnosis and treatment, while also helping people capture and share meaningful moments. Through its commitment to innovation, sustainability and human connection, FUJIFILM works to create a healthier and more connected world for future generations.

Cancer Research UK (CRUK) is the world’s leading independent funder of cancer research, dedicated to saving lives through research, influencing, and campaign-led action. By funding world-class science across prevention, early detection, and treatment, CRUK has helped double cancer survival in the UK over the past 50 years and contributed to major breakthroughs globally. 

Recognising that cancer is a global issue, CRUK works extensively across international boundaries to tackle the toughest challenges in cancer control. Through pioneering global initiatives—such as Cancer Grand Challenges, the International Alliance for Cancer Early Detection (ACED), and the International Cancer Benchmarking Partnership (ICBP)—it brings together multidisciplinary teams worldwide to accelerate innovation and address global variances in patient outcomes. 

Policy engagement is central to Cancer Research UK’s mission. CRUK leverages rigorous scientific evidence to influence government policy, championing transformative measures in tobacco control, early diagnosis, and HPV vaccination. The International Cancer Prevention (ICP) programme supports civil society organisations and research institutions in multiple low- and middle-income countries, building local advocacy capacity and driving evidence-based legislation that promotes Tobacco Control and HPV prevention.  Through international scientific collaboration and active policy advocacy at the global level, Cancer Research UK is committed to helping people around the world live longer, better lives, and to shaping a future where we will beat cancer.

The Bristol Myers Squibb Foundation (BMS Foundation), an independent charitable organisation, is focused on advancing health equity and dedicated to its mission to improve global health.

By empowering local communities to create lasting impact, the BMS Foundation’s vision is for a future where all people, regardless of where they live, can achieve their best possible health through strong local healthcare systems. It invests in capacity building and health systems strengthening programs to expand access to care for medically underserved populations in the geographies where it is focused, including Brazil, India, Sub-Saharan Africa and the United States.

Through its strategic grantee partners and locally led solutions, the BMS Foundation advances innovative approaches that ultimately improve patient outcomes and promote health equity worldwide.

Bristol-Myers Squibb is a global BioPharma company firmly focused on its mission to discover, develop and deliver innovative medicines to patients with serious diseases.